Monte Rosa Therapeutics (GLUE) Enterprise Value: 2023-2025
Historic Enterprise Value for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $56.0 million.
- Monte Rosa Therapeutics' Enterprise Value fell 71.95% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 291.69%. This contributed to the annual value of $45.4 million for FY2024, which is 2.43% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Enterprise Value is $56.0 million, which was up 338.88% from -$23.4 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Enterprise Value registered a high of $331.7 million during Q1 2023, and its lowest value of -$49.7 million during Q1 2025.
- Over the past 3 years, Monte Rosa Therapeutics' median Enterprise Value value was $80.1 million (recorded in 2024), while the average stood at $128.2 million.
- Its Enterprise Value has fluctuated over the past 5 years, first increased by 11.68% in 2024, then slumped by 129.28% in 2025.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Enterprise Value stood at $46.5 million in 2023, then declined by 2.43% to $45.4 million in 2024, then plummeted by 71.95% to $56.0 million in 2025.
- Its Enterprise Value was $56.0 million in Q3 2025, compared to -$23.4 million in Q2 2025 and -$49.7 million in Q1 2025.